The massive rise of patient advocacy in the US has led to an aggressive, if inadvertent, contest between disease-specific lobbyists. Advocacy groups say they're just trying to get taxpayer-backed research dollars distributed equitably according to public health need and they deny any outright competition with one another. But with research budgets shrinking, advocacy becomes a zero-sum game. Some scientists worry that pitting one disease against another threatens the leadership of government funding bodies—not to mention the basic research enterprise. Virginia Hughes reports.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Marshall, E. Science 276, 344–346 (1997).
Best, R.K. Am. Sociol. Rev. 77, 780–803 (2012).
Gillum, L.A. et al. PLoS ONE 6, e16837 (2011).
Gross, C.P., Anderson, G.F. & Powe N.R. N. Engl. J. Med. 340, 1881–1887 (1999).
Sampat, B.N. Buterbaugh, K. & Perl, M. Milbank Q. 91, 163–185 (2013).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hughes, V. The disease olympics. Nat Med 19, 257–260 (2013). https://doi.org/10.1038/nm0313-257
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0313-257